InvestSMART

Anteris Technologies Ltd (ASX: AVR) - Announcements

Current share price for AVR : $12.100 0.23 (1.87%)+

ASX company news and announcements for Anteris Technologies Ltd (AVR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Anteris Technologies Ltd (AVR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Anteris Technologies Ltd (AVR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Anteris Technologies Ltd (AVR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$183 Suspension from Official Quotation 29 Dec 2020 11:24AM $3.750 $12.100 risen by 222.67%
$183 Trading Halt 23 Dec 2020 9:25AM $3.750 $12.100 risen by 222.67%
$183 Final Director's Interest Notice 17 Dec 2020 8:05PM $3.840 $12.100 risen by 215.10%
$183 Non-Executive Director Resignation 16 Dec 2020 4:19PM $3.800 $12.100 risen by 218.42%
$183 Change of Director's Interest Notice 15 Dec 2020 11:54AM $3.950 $12.100 risen by 206.33%
$183 Cancelled Options 15 Dec 2020 11:50AM $3.950 $12.100 risen by 206.33%
$183 AVR presenting Switzer Small & Micro-Cap Conference 27 Nov 2020 8:47AM $3.670 $12.100 risen by 229.70%
$183 DurAVR SELECTED AS A BEST INNOVATION - PCR LONDON VALVES 23 Nov 2020 9:14AM $3.800 $12.100 risen by 218.42%
$183 Anteris to Present at Credit Suisse Structural Heart Forum 19 Nov 2020 11:31AM $3.560 $12.100 risen by 239.89%
$183 Anti-calcification Comparison Study Interim Results 10 Nov 2020 10:46AM $3.700 $12.100 risen by 227.03%
$183 Appendix 3G 6 Nov 2020 1:39PM $3.870 $12.100 risen by 212.66%
$183 Appendix 4C - quarterly 16 Oct 2020 10:58AM $4.050 $12.100 risen by 198.77%
$183 Extension of Loan Facility 15 Oct 2020 4:15PM $4.040 $12.100 risen by 199.50%
$183 DurAVR valve patient outcomes exceed expectations 9 Oct 2020 10:03AM $3.920 $12.100 risen by 208.67%
$183 Cancelled Options 24 Sep 2020 4:00PM $4.010 $12.100 risen by 201.75%
$183 Change in substantial holding 21 Sep 2020 10:52AM $3.830 $12.100 risen by 215.93%
$183 Anteris Granted US Patent 8 Sep 2020 2:27PM $4.070 $12.100 risen by 197.30%
$183 TAVR Medical Advisory Board Appointment 31 Aug 2020 8:14AM $3.900 $12.100 risen by 210.26%
$183 Operations update 28 Aug 2020 2:32PM $3.970 $12.100 risen by 204.79%
$183 Appendix 4D and Half Yearly Financial Report 20 Aug 2020 1:42PM $4.070 $12.100 risen by 197.30%
$183 Unusual Trading Patterns 30 Jul 2020 2:54PM $3.450 $12.100 risen by 250.72%
$183 TAVR Key Opinion Leader Symposium 28 Jul 2020 2:20PM $3.530 $12.100 risen by 242.78%
$183 Response to Market Speculation 24 Jul 2020 4:00PM $3.730 $12.100 risen by 224.40%
$183 Expired Options 24 Jul 2020 12:07PM $3.610 $12.100 risen by 235.18%
$183 Appendix 4C - quarterly 22 Jul 2020 4:41PM $3.690 $12.100 risen by 227.91%

651 - 675 of 707 results

Page 27 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.